Skip to content

Clinical application study of H2AX in evaluation of endometrial receptivity

Clinical application study of H2AX in evaluation of endometrial receptivity

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037581
Enrollment
Unknown
Registered
2020-08-29
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Gold Standard:1. Endometrial receptivity indexes: A. Blood flow signals detected by B-ultrasound and molecular tags such as H2AX detected in menstrual blood endometrial cells
B. On trigger day, endometril thickness and blood flow signal detected by B-ultrasound and H2AX and other molecular tags such as H2AX detected in endometria
Index test:The&#32
expression&#32
of&#32
H2AX,&#32
gammaH2AX,EGFR/HIF-1alpha/VEGF&#32
be&#32
in&#32
tissues/cells&#32
from&#32
patients&#32
with&#32
and&#32
non-RIF&#32
(i.e.,first-time&#32

Sponsors

Shuguang Hospital, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. RIF patients with more than or equal to 2 times of IVF-ET treatment and the first transplant patients (non-RIF patients); 2. Assisted pregnancy with in vitro fertilization-embryo transfer after ovulation induction by unified antagonist regimen; 3. Blastocyst sterility patients with normal PGS.

Exclusion criteria

Exclusion criteria: 1. Patients with IVF contraindications; 2. Blastocyst sterility patients with abnormal PGS; 3. Patients with stage III/IV endometriosis, based on the Endometriosis grading system of the American Society for Reproductive Medicine; 4. Adenomyosis, uterine fibroids compression uterine cavity line and untreated endometrial diseases; 5. Untreated hydrosalpinx; 6. Patients with a history of chronic diseases such as diabetes, hypertension, hyperthyroidism/hypothyroidism, heart disease, liver and kidney diseases, combined with serious primary medical diseases and psychosis.

Design outcomes

Primary

MeasureTime frame
H2AX;gammaH2AX;

Countries

China

Contacts

Public ContactChunxia Ren

Shuguang Hospital, Shanghai University of Traditional Chinese Medicine

renchunxia2018@shutcm.edu.cn+86 13861683629

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026